Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Overall, the therapy worked very well in the mice used in the study. The first human clinical trial will be in adult brain cancers.
The researchers are now designing a first-in-human clinical trial to test the effectiveness of this approach in patients.
A look back at some of the major news stories we covered this year.
Long-term remission seen in children with leukemia and adults with lymphoma.
Customized cell therapy plus Imbruvica leads to high response rate.
We asked the experts what they think will be the next big breakthroughs.
Half of those treated with the experimental immunotherapy bb2121 no longer had detectable cancer.
The new therapies include immune checkpoint inhibitors; therapeutic vaccines; CAR T-cell therapies; and “conjugate” drugs.
Rosenberg, June and Allison win award for breakthroughs in cancer immunotherapy.
The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.
Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy.
Future clinical trials will explore whether cellular and antibody-based therapies can be beneficial as earlier-stage treatments.
Study finds engineered that natural killer cells are equally effective with less toxicity.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.